It is essential that sponsors of drugs, devices and biologics develop responses to adverse FDA action that consider regulatory compliance goals as well as the litigation consequences.  This session will provide: a brief review of FDA's risk management and corrective action tools; general principles for responding to and negotiating with FDA or other regulatory authorities; SOPs and training needs for safety action procedures and hypothetical scenarios in which external considerations may affect the manufacturer's regulatory response.